Yesterday we made a comment on Prometheus Bioscience (NASDAQ: RXDX) and how, at the very opening of premarket trade this morning, there was a profit making opportunity.
For Merck (NYSE: MRK) made an agreement over the weekend to buy RXDX at $200 per share in cash. We said that the price would rapidly rise to the $180 to $190 level as a result. No, we really did publish this about Prometheus Bioscience yesterday.
The point we made was that not everyone on the market would be quite up to date with this. Not at 4 am they wouldn't. So, if there was anyone out there willing to sell RXDX stock at something close to Friday's price then buy, buy, buy. In fact, we said fill your boots:
“If you find someone who is selling at that uninformed price then don't just grab with your hands, or stuff into your pockets - this is a time to fill your boots, fill your boots to overflowing. Oh, and happy hunting.”
And so it came to pass:

Prometheus Bioscience premarket trades from NASDAQ
At that on the dot of 4 am someone was able to buy Prometheus at $130 per share. It looks very like they were able to sell again, mere moments later, at $191.15. Agreed, being able to trade in 80 pieces isn't quite filling your boots but if that's the maximum amount of free money the market is going to allow then that's that. It's still $6,492 in profit in under a minute on a $10,400 outlay.
Such opportunities are, of course, rare. But they do indeed happen. As this did indeed happen and as we predicted it would. A fleeting opportunity even, one not all that large in size. And as far as we can tell from NASDAQ (we obviously don't know what happened at CfD brokers and the like) only one person in the world managed to take advantage of that RXDX opportunity.
Stock markets do, sometimes, offer what is really very close indeed to free money. We do have, of course we do, monstrously large egos but even we'd not insist that that one trader did so on the basis of our advice. But the advice was there, ahead of time, and it did work.



